Bridgebio Pharma, Inc. · NASDAQ:BBIO
Bridgebio Pharma — 44th Annual J.P. Morgan Healthcare Conference 2026
48 slides from Bridgebio Pharma's conference presentation, Jan 12, 2026
Slide 1: J.P. Morgan Presentation
J.P. Morgan Presentation January 12, 2026
Slide 2: Forward Looking Statements and Disclaimer
Forward Looking Statements and Disclaimer The presentation contains forward-looking statements. Statements made or presented may include statements that are not historical facts and are considered forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended, and Sectio
Slide 3: Thank you to our investors for enabling us to deliver hope and medicines
Thank you to our investors for enabling us to deliver hope and medicines to the patients that we serve > 8,500 patients impacted by our therapies Obtained Approval for 3 Medicines 2 Positive + 2 Ongoing Phase 3 Results Pivotal Trials 15 > 70 > 35 19 < $40M active trials papers academic INDs spen
Slide 4: Today we will review commercial/late-stage programs and early-stage progress
Today we will review commercial/late-stage programs and early-stage progress Attruby revenue Late-stage data and regulatory progress Early-stage research and our potentially best-in-class EPP program 4
Slide 5: $146M Q4 2025 Net Product Revenue
NEW INFORMATION Continued Attruby commercial momentum $146M 1 Q4 2025 Net Product Revenue 1Represents preliminary, unaudited results for the fourth quarter ended December 31, 2025, based on management’s current expectations and subject to completion of year end audit procedures. See Forward Looking
Slide 6: Continued Attruby commercial momentum and patient impact
NEW INFORMATION Continued Attruby commercial momentum and patient impact 6,629 1,632 >25% Unique U.S. patient Unique U.S. Estimated share of prescriptions for Attruby prescribing HCPs NBRx for Attruby As of December 31st, 2025 6
Slide 7: We continue to study the impact of Attruby across clinical dimensions
We continue to study the impact of Attruby across clinical dimensions First and ONLY… 1 month 42% 50% Reduction in cumulative Reduction in composite …approved product Reduction in the cardiovascular of all-cause mortality with a cumulative frequency outcomes within the and recurrent label specifying
Slide 8: Attruby significantly reduced the risk of CVM or recurrent CVH through Month 30
Attruby significantly reduced the risk of CVM or recurrent CVH through Month 30 vs. placebo by 49% with separation of curves starting by Month 1 Estimated Mean Cumulative Events of CVM or Recurrent CVH Through Month 30 (mITT Population, Acoramidis, n = 409; Placebo, n = 202) Acoramidis Placebo (n =
Slide 9: Attruby's advantages stem from being the most potent stabilizer
Attruby’s advantages stem from the fact that it is the most potent stabilizer Acoramidis is the only stabilizer with The multiplicity of advantages to superior stabilization continue to be better “near complete” stabilization in the label understood and elucidated in novel research “Our thermodynami
Slide 10: BridgeBio has initiated a depleter program for ATTR-CM disease reversal
Along with work on Attruby, BridgeBio has initiated a depleter NEW PROGRAM program to explore the potential of ATTR-CM disease reversal ATTR-CM Disease Pathophysiology Led by Renowned Antibody Expert Existing TTR therapies target upstream …but unmet need remains for patients with existing tetramer s
Slide 11: BridgeBio's depleter is engineered across novel properties for differentiation
BridgeBio’s depleter is engineered across 4 novel properties for NEW PROGRAM potential differentiation on clinical efficacy and dosing convenience Depleter Mechanism of Action BridgeBio’s Differentiated Target Properties 1 Improved fibril:tetramer binding ratio • >10× preferential binding to misfold
Slide 12: Limitations of first-generation depleters highlight next-generation opportunity
Limitations of first-generation depleters highlight the opportunity NEW PROGRAM for a next-generation depleter to better serve patient needs Competitors BridgeBio Property Company A Company B BridgeBio’s Depleter Why it Matters • Maximizes on-target Improved >10× preferential binding to engagement
Slide 13: BBP-418
BBP-418 Addressable people by indication (current population with addressable mutations) Status: Positive Phase 3 Interim Result in LGMD2I/R9 9K 2K Fukuyama congenital muscular dystrophy (Japan) 7K LGMD2I/R91,2 (US + EU) (Phase 3 fully enrolled and positive interim analysis topline announced as of O
Slide 14: Clinically meaningful improvement across all pre-specified endpoints
Unprecedented, clinically meaningful improvement across all pre-specified endpoints and well-tolerated safety profile at interim analysis MET PRIMARY AND ALL KEY SECONDARY ENDPOINTS VS. PLACEBO Improved Faster 1.8x 82% ambulation pulmonary Well increase in decrease in CK compared to function tolerat
Slide 15: Planned subgroup analyses show consistent benefit of BBP-418
Planned subgroup analyses show consistent benefit of BBP-418 vs. NEW INFORMATION placebo in all subgroups across α-controlled efficacy endpoints at 12 months Biomarker Glycosylated αDG (% of control) Serum creatine kinase (U/L) LS Mean Difference (95% CI) LS Mean Difference (95% CI) L276I homozygous
Slide 16: BBP-418 2.6 point benefit on NSAD relative to placebo
BBP-418 treated patients experienced highly clinically meaningful NEW INFORMATION 2.6 point benefit on NSAD relative to placebo even at early 12-month timepoint Improved gross motor function Even a 1-point difference in NSAD can mean… Change from baseline in NSAD (points) Requiring Able to get up 1.
Slide 17: Successful FDA meeting; NDA oriented toward traditional approval
We completed a successful meeting with the FDA and they NEW INFORMATION recommended orienting our NDA toward traditional and full approval All data from the Phase 3 FORTIFY study were presented to the agency, including key sensitivities FDA acknowledged the data “…demonstrate consistent treatment ef
Slide 18: Encaleret
Encaleret Addressable people by indication in US (current population with ADH1) Status: Positive Phase 3 Result in ADH1 12K Individuals with ADH1 ~12K ADH1 prevalent population in the US based on 4 population databases1-2 9K Symptomatic 73% of patients with ADH1 are symptomatic3 3K – 5K Currently Ad
Slide 19: CALIBRATE achieved and exceeded all upside target criteria
CALIBRATE achieved & exceeded all criteria set forth as an upside target, with a 76% responder rate following 24 weeks of encaleret treatment Upside Target Clinical Profile Outcome Observed Statistically significant primary analysis result Primary endpoint met (p <0.0001) demonstrating compared to
Slide 20: >90% of CALIBRATE participants demonstrated a pharmacologic response
>90% of CALIBRATE participants administered encaleret demonstrated a pharmacologic response Week 4 Week 24 Primary Analysis – Within Group SoC Encaleret p-value3 (N=45) (N=45) Number of Participants Meeting The Primary Endpoint 2 34 (Responder status)1,2 Proportion, % 4% 76% Difference in Proportion
Slide 21: BridgeBio is pioneering efforts to enable the successful launch of encaleret
BridgeBio is pioneering efforts to enable the successful launch of NEW INFORMATION encaleret, potentially the first calcilytic molecule to be approved for any condition Expanded availability of testing Enabled creation of new Enabled update to treatment through sponsored genetic ICD-10 code dedicate
Slide 22: Over 24 months, >1,700 unique patients diagnosed with ADH in the US
Over a 24-month period, >1,700 unique patients were diagnosed NEW INFORMATION with ADH in the US Cumulative ADH Patients Diagnosed2 1,800 1,600 1,400 1,200 17% CMGR 1,000 800 600 400 200 0 10/23 01/24 04/24 07/24 10/24 01/25 04/25 07/25 10/25 ~50% of HCPs diagnosing ADH patients manage ≥5 non-surgic
Slide 23: Encaleret potential oral option for chronic hypoparathyroidism
Encaleret has the potential to be an orally administered option for NEW INFORMATION patients with chronic hypoparathyroidism (CHP) Announcing the RECLAIM-HP Encaleret has the potential to normalize Phase 3 Study of Encaleret in CHP blood and urine calcium in CHP patients Initiating in 2026 • CHP pat
Slide 24: RECLAIM-HP Phase 3 study to initiate in Summer 2026
RECLAIM-HP Phase 3 study of encaleret in chronic NEW INFORMATION hypoparathyroidism to initiate in Summer 2026 RECLAIM-HP: Global, multi-center, randomized, double-blind, placebo-controlled study Double-blinded treatment period Encaleret + Conventional Therapy1 Encaleret + Conventional Therapy1 Titr
Slide 25: Infigratinib in achondroplasia
Infigratinib Status: LPLV in Phase 3 in achondroplasia 55,000 Represents individuals with diagnosed and addressable ACH achondroplasia 7K population with open growth plates in US/EU $5B+ potential global market 1CDC birth estimates; EU Eurostats birth estimates; Foreman, et al. Am J Med Genet. 2020.
Slide 26: LPLV achieved on PROPEL 3; topline expected Q1
We have achieved LPLV on PROPEL 3 and expect topline in Q1, NEW INFORMATION and we have made significant operational progress on expansion opportunities Last participant last visit completed; Topline expected Q1 2026 Pivotal Phase 3 Study in children and adolescents (3-<18 years) with achondroplasia
Slide 27: Infigratinib: Defining characteristics of a potentially best-in-class program
Infigratinib: Defining characteristics of a potentially best-in-class program in the ACH landscape Designed to target achondroplasia at its genetic source: FGFR3 overactivation Addresses not just overactivation of the MAPK pathway (chondrocyte hypertrophy), but also STAT1 (chondrocyte proliferation)
Slide 28: Infigratinib sprinkle capsules are being developed for oral administration
Infigratinib sprinkle capsules are being developed for oral administration 1,2 • Infigratinib is being studied in children over 3 years of age with achondroplasia Capsules (17 mm long*) Granules (2 mm long) (0.25 kg/mg/day) as a sprinkle capsule • Capsules can be swallowed whole or content (granules
Slide 29: Validated evidence-based perspective to forecasting market share
BridgeBio has developed a validated evidence-based perspective to forecasting market share performance Comprehensive market surveys Analog research shows 2nd entrants ML-based empirical analysis enables indicated 30-40%+ Attruby share achieve average ~37% share high fidelity drug launch modeling Att
Slide 30: Infigratinib could capture >50% of treated market share
Our market research indicates that infigratinib could capture >50% of treated market share, primarily driven by the favorable oral administration and MOA Potential share for ACH children Attribute TPP for testing market share % of treated children • Children (3 – 18 years) with (N = 95 HCPs; represe
Slide 31: BBP-812
BBP-812 Status: Pivotal trial ongoing in Canavan disease Canavan disease is a fatal, neurodegenerative and ultra- rare pediatric disease with no approved therapies • Canavan disease (CD) is an ultra-rare neurodegenerative disease with ~1,000 patients across the US and EU • CD is usually fatal within
Slide 32: Current path to a potential BLA filing in 2027
Current path to a potential BLA filing in 2027 based on reductions NEW INFORMATION in urine NAA (surrogate endpoint) supported by motor function improvements Urine N-acetylaspartic acid (NAA) levels Hammersmith Infant Neurological Examination (HINE-2) Trajectory Change in HINE-2 Total Score Months s
Slide 33: Centralized scale + disease-level focus = multiple focused launches
Centralized scale + disease-level focus = ability to have multiple, focused launches Benefits of centralized Benefits of execution at the commercial model decentralized program level Deep program expertise Build once, scale many Dedicated affiliate teams stay with Build commercial capabilities once
Slide 34: Our future: It's still day 1 in genetic disease
Our future: It’s still day 1 in genetic disease 34
Slide 35: We are at day 1 of genetic medicine
We are at day 1 of genetic medicine Today, missing heritability is being explained “..we show that 12,111 independent SNPs that are significantly associated with height account for nearly all of the common SNP- based heritability.” - Yengo et al, Nature 2022 “We identified 15 traits with no signific
Slide 36: From the missing heritability to the missing mechanism
From the missing heritability to the missing mechanism • Larger Biobanks: UKB, • Perturb-seq to perturb Saturation of genetic High throughput AOU, ADG, etc. every single gene across variants affecting perturbation • WGS for non-coding the genome human traits assays rare variants • MAVE to perturb ev
Slide 37: The GondolaBio pipeline features a diverse set of programs
Example #1: The GondolaBio pipeline features a diverse set NEW INFORMATION of programs across therapeutic areas and modalities Patient Population IND Indication Discovery Lead Op Phase 1 Phase 2 (US+EU) Enabling Erythropoietic Protoporphyria (EPP) 25k Autosomal Dominant Polycystic Kidney Disease (AD
Slide 38: The Phase 2 EPP program targets a genetic disease with high unmet need
Example #2: The Phase 2 Erythropoietic Protoporphyria (EPP) program targets a genetic disease with high unmet need EPP has severe health consequences… …and affects a large patient population ~20-25K+ ~14K ~14K ~13K ~12K ~10K ~7.5K US & EU pop Sunlight causes skin damage and excruciating pain leading
Slide 39: PORT-77
The pathomechanism of EPP is driven by the heme biosynthesis intermediate protoporphyrin nine (PPIX) in plasma and bile Inhibition of ABCG2 prevents the The Portal small molecule PORT-77 is designed as a potentially transport of PPIX out of red blood best-in-class disease modifying therapy to meet t
Slide 40: PORT-77 targets EPP at its source by preventing PPIX transport
PORT-77 targets EPP at its source by preventing transport of PPIX out of red blood cells into the plasma, skin, and bile Mechanism ABCG2 inhibition keeps PPIX out of PORT-77 is a small molecule ABCG2 Which addresses all aspects of EPP safely the plasma, skin, and bile inhibitor and rapidly Addresses
Slide 41: PORT-77 is being investigated in the GATEWAY Phase 2a trial
PORT-77 is being investigated in the GATEWAY Phase 2a trial Period 1 Period 2 Follow-up (treatment sequence blinded to participant) High Dose PORT-77 Placebo Low Dose PORT-77 Days 1-4 Days 5-8 Day 9 Design Endpoints Study population Single-blind, randomized, placebo- Change in plasma PPIX as S
Slide 42: PORT-77 has shown the largest PPIX reduction seen to date
PORT-77 has shown the largest PPIX reduction seen to date, NEW INFORMATION reaching steady state within days Baseline Day 1 Day 2 Day 3 Day 4 0% 0 0.5 1 1.5 2 2.5 3 3.5 4 Dose dependent -10% reductions in Plasma PPIX (relevant disease -20% compartment) observed -30% PPIX reduction in Literature and
Slide 43: Significant PPIX reduction seen in the Phase 2a regardless of baseline
Significant PPIX reduction seen in the Phase 2a, NEW INFORMATION regardless of baseline PPIX value % PPIX reduction between Baseline and Steady State: GATEWAY PPIX reduction at Steady State (n = 12) Steady State 120 Baseline PPIX value (ug/dL) (D4 12H) Significant Subject K: -41% Subject A 41 -19% r
Slide 44: PORT-77 has a clean safety profile across dose levels
PORT-77 has a clean safety profile across dose levels with no SAEs or NEW INFORMATION safety and tolerability signals identified to date in the Phase 1 and Phase 2a trials Predose Placebo PORT-77 Treatment (n=12) (n=12) (n=12) Subjects with any TEAE 3 (25%) 7 (58%) 5 (42%) TEAEs leading to 0 0 0 dis
Slide 45: The EPP program has achieved proof-of-concept
The EPP program has achieved proof-of-concept for a potential best-in-disease profile Consistent and potential best-in-class PPIX reduction; Dual-mechanism independently treating sunlight and liver symptoms Clean safety profile with no notable AEs in treatment group and lack of CNS effects to date P
Slide 46: Continued progress across the BridgeBio ecosystem
Continued progress across the BridgeBio ecosystem Discovery Lead Op Pre-IND Proof-of-Concept Pivotal Commercial Hereditary KRASG12C Canavan BVMD Pancreatitis ON / OFF ADPKD ADH1 SYNGAP1 TSC EPP Preeclampsia Kidney Hypochondroplasia Hypochon Chronic HP CMT1A ATTR-CM Dup15q Stones EPP PanKRAS Achondro
Slide 47: Key takeaways today – significant momentum across the portfolio
NEW INFORMATION Key takeaways today – significant momentum across the portfolio • Attruby: $146M1 in Q4 net product revenue; 6,629 unique patient prescriptions; and >25% NBRx share ATTR-CM • New antibody depleter program announced for ATTR-CM • LPLV for Phase 3 achondroplasia trial achieved Infigrat
Slide 48: Well-financed to hit a drumbeat of potential milestones in 2026 and beyond
We are well-financed to hit a drumbeat of potential milestones NEW INFORMATION in 2026 and beyond 1H 2026 Infigratinib: ACH Topline BridgeBio ended 2025 Encaleret: Initiate P2/3 pediatric ADH1 with $587.5M1 in cash, Encaleret: NDA filing cash equivalents, and marketable securities BBP-418: NDA filin
BridgeBio Pharma — 44th Annual J.P. Morgan Healthcare Conference 2026 on 6ix